A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke

NCT07205328 | Recruiting Phase 2

• 1 other identifier: MT200605-II-C01
• Study Type: interventional
• Target: 360
• Locations: 1 country
• Sites: 1

Brief Summary

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB). It exerts brain-derived neurotrophic factor (BDNF)-like effects, protecting the structure and function of neural tissues in the brain. Simultaneously, it enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities. MT200605 is anticipated to confer pharmacological benefits including the reduction of neuronal apoptosis, antioxidant/free radical scavenging activity, anti-inflammatory effects, modulation of neuronal excitability, and amelioration of cerebral ischemic injury in patients with ischemic stroke. This Phase II exploratory study will be conducted across 32 research centers in China. It plans to enroll 360 patients diagnosed with acute ischemic stroke within 24 hours of onset. Subjects will be randomized to receive either a high, medium, or low dose of MT200605 or a placebo, in addition to standard medical care. The primary efficacy endpoint is the proportion of subjects achieving a modified Rankin Scale (mRS) score of ≤1 at 3 months post-stroke. Secondary efficacy endpoints include the reduction in the National Institutes of Health Stroke Scale (NIHSS) score from baseline at day 14, among others.

Conditions

Acute Ischemic Stroke

Outcome Measures

Primary Outcomes (1)

• Modified Rankin Scale（mRS）

  90 ± 5 days after the onset of stroke

Study Arms (4)

MT200605 Low-dose group

EXPERIMENTAL

Standard medical treatment + MT200605 10mg, twice daily, intravenous infusion, for 14 consecutive days;

Drug: MT200605

MT200605 Medium-dose group

EXPERIMENTAL

Standard medical treatment + MT200605 20mg, twice daily, intravenous infusion, for 14 consecutive days;

Drug: MT200605

MT200605 High-dose group

EXPERIMENTAL

Standard medical treatment + MT200605 40mg, twice daily, intravenous infusion, for 14 consecutive days

Drug: MT200605

Placebo Group

PLACEBO COMPARATOR

Standard medical treatment + placebo, twice daily, intravenous infusion, for 14 consecutive days.

Drug: Placebo

Interventions

MT200605 DRUG

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

MT200605 High-dose group

Placebo DRUG

The placebo does not contain any active ingredients.

Placebo Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 80 years old (inclusive), male or female ;
• Diagnosed with ischemic stroke according to the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023";
• The time from the onset of the disease to the expected administration of the investigational drug will be within 24 hours., including patients who have not received reperfusion therapy or those have received intravenous thrombolysis treatment;
• The NIHSS score at admission is between 6 and 25 (inclusive), and the sum of the scores for the 5th（upper limb movement） and the 6th（ lower limb movement） is ≥ 2 points;
• The mRS score before this onset of stroke is 0 to 1, and there are no obvious clinical symptoms and signs that affect the NIHSS score;
• Able to understand and cooperate with the process of this study, and voluntarily sign the informed consent.

You may not qualify if:

• After the onset of the disease, obvious consciousness disorders occurre, and the score of the NIHSS item for the 1a level of consciousness is \>1 point;
• Transient ischemic attack (TIA);
• This acute ischemic stroke requires endovascular treatment (including intravenous thrombolysis, mechanical thrombectomy, angioplasty);
• At the time of admission, already known severe active kidney disease, renal insufficiency; or serum creatinine \> 1.5 × ULN;
• Severe active liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis, etc.; or ALT or AST \> 2.0 × ULN;

Sponsors & Collaborators

• Shaanxi Micot Pharmaceutical Technology Co., Ltd.: lead

Study Sites (1)

BeiJing Tiantan Hospital

Beijing, Beijing Municipality, 100070, China

RECRUITING

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

YongJun Wang, Doctor

CONTACT

010-59978538; yongjunwang1962@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 25, 2025
• First Posted: October 3, 2025
• Study Start: October 1, 2025
• Primary Completion: May 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: October 3, 2025

Record last verified: 2025-07

Locations

CN (1)